Amendments to the Claims

- 1. (Canceled)
- 2. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole anhydrate of structural formula I:</u>

<u>characterized</u> The crystalline anhydrate of Claim 1 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.19, 6.09, 4.57, 4.19, 4.06, and 3.20 angstroms.

- 3. (Original) The crystalline anhydrate of Claim 2 further characterized by the X-ray powder diffraction pattern of FIG. 1.
- 4. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole anhydrate of structural formula I:</u>

<u>characterized</u> The <u>crystalline anhydrate of Claim 1 characterized</u> by the solid state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 2.

5. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole anhydrate of structural formula I:</u>

<u>characterized</u> The crystalline anhydrate of Claim 1 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 158.9, 158.2, 143.0, 129.3, 127.2, 43.5, 36.6, 26.4, and 7.6 p.p.m.

6. (Original) The crystalline anhydrate of Claim 5 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 3.

7. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole anhydrate of structural formula I:</u>

<u>characterized</u> The crystalline anhydrate of Claim 1 characterized by the differential scanning calorimetric (DSC) curve of FIG. 4.

8. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole anhydrate of structural formula I:</u>

<u>characterized</u> The crystalline anhydrate of Claim 1 characterized by the thermogravimetric analyis (TGA) curve of FIG. 5.

9. (Canceled)

10. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole monohydrate of structural formula I:</u>

<u>characterized</u> The crystalline monohydrate of Claim 9 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 8.08, 6.49, 5.43, 5.39, 4.38, 4.10, 3.18, and 2.74 angstroms.


- 11. (Original) The crystalline monohydrate of Claim 10 further characterized by the X-ray powder diffraction pattern of FIG. 6.
- 12. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole monohydrate of structural formula I:</u>

<u>characterized</u> The <u>crystalline monohydrate of Claim 9 characterized</u> by the solid state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 7.

13. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole monohydrate of structural formula I:</u>

<u>characterized</u> The crystalline monohydrate of Claim 9 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 161.5, 157.8, 143.4, 132.3, 130.0, 128.5, 126.9, 125.9, 45.5, 37.2, 26.4, and 7.7 p.p.m.

- 14. (Original) The crystalline monohydrate of Claim 13 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 8.
- 15. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole monohydrate of structural formula I:</u>



<u>characterized</u> The erystalline monohydrate of Claim 9 characterized by the differential scanning calorimetric (DSC) curve of FIG. 9.

16. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole monohydrate of structural formula I:</u>

<u>characterized</u> The <u>crystalline monohydrate of Claim 9 characterized</u> by the thermogravimetric analyis (TGA) curve of FIG. 10.

17-20 (Canceled)

21. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole toluene solvate of structural formula <u>I:</u></u>

<u>characterized</u> The crystalline toluene solvate of Claim 20 characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.13, 6.74, 5.95, 4.38, 3.83, 3.61, 3.42, 3.14, and 2.30 angstroms.

22. (Original) The crystalline toluene solvate of Claim 21 further characterized by the X-ray powder diffraction pattern of FIG. 11.


23. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole toluene solvate of structural formula <u>I</u>:</u>

characterized The crystalline toluene solvate of Claim 20 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals with chemical shift values of 165.2, 158.8, 143.5, 136.0, 128.8, 128.0, 127.4, 120.0, 119.0, 117.6, 36.6, 26.8, 21.0, and 7.8 p.p.m.

- 24. (Original) The crystalline toluene solvate of Claim 23 characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 12.
- 25. (Currently Amended) <u>Crystalline 3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole toluene solvate of structural formula <u>I:</u></u>

<u>characterized</u> The crystalline toluene solvate of Claim 20 characterized by the differential scanning calorimetric (DSC) curve of FIG. 13.

26. (Currently Amended) <u>3-[1-(4-Chlorophenyl)-*trans*-3-fluorocyclobutyl]-4,5-dicyclopropyl-*r*-4*H*-1,2,4-triazole of structural formula I:</u>



<u>characterized</u> The crystalline toluene solvate of Claim 20 characterized by the thermogravimetric analysis (TGA) curve of FIG. 14.